Karyopharm Therapeutics Inc. (KPTI)Healthcare | Biotechnology | Newton, United States | NasdaqGS
8.61 USD
-0.05
(-0.577%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.61 Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:43 p.m. EDT
KPTI is showing strong short-term momentum driven by a phase 3 trial catalyst and a rebound from recent lows, but it remains a high-risk growth story for the long term. The short signal is weak (rating 4) due to the stock's recovery toward its moving averages and positive options positioning, but the long signal is poor (rating 2) due to negative EPS, high debt, and negative operating margins. While not a safe dividend play, the speculative options activity suggests short-term traders are positioning for a continuation of the upside move, despite the fundamental financials remaining fragile. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.229327 |
| AutoTheta | 0.241688 |
| AutoETS | 0.242462 |
| AutoARIMA | 0.289420 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 1.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.241 |
| Excess Kurtosis | -1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 13.358 |
| Market Cap | 194,097,936 |
| Forward P/E | -1.97 |
| Beta | 0.40 |
| Profit Margins | -134.21% |
| Website | https://www.karyopharm.com |
As of April 18, 2026, 11:43 p.m. EDT: Options data reveals a distinct 'risk reversal' or short-term bullish skew. Call positioning heavily favors the upside with significant Open Interest (OI) concentration at strikes 10.0 and 20.0 for near-term expirations, while implied volatility (IV) for OTM calls is suppressed relative to puts. Conversely, put concentration is skewed toward downside strikes (2.5 and 5.0), suggesting a 'safe money' floor is being built. However, the volume at OTM call strikes (10.0, 20.0) exceeds put volume at similar strikes, indicating speculative play is on the upside. The scarcity of call data for later months indicates the bulk of speculative flow is focused on price acceleration within the next 3-6 months.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5944444 |
| Address1 | 85 Wells Avenue |
| Address2 | 2nd Floor, Suite 210 |
| All Time High | 735.075 |
| All Time Low | 3.51 |
| Ask | 8.65 |
| Ask Size | 2 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 603,890 |
| Average Daily Volume3 Month | 1,000,693 |
| Average Volume | 1,000,693 |
| Average Volume10Days | 603,890 |
| Beta | 0.404 |
| Bid | 8.54 |
| Bid Size | 2 |
| Book Value | -15.997 |
| City | Newton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.61 |
| Current Ratio | 1.12 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.89 |
| Day Low | 8.465 |
| Display Name | Karyopharm Therapeutics |
| Earnings Call Timestamp End | 1,770,901,200 |
| Earnings Call Timestamp Start | 1,770,901,200 |
| Earnings Timestamp | 1,770,903,000 |
| Earnings Timestamp End | 1,778,502,600 |
| Earnings Timestamp Start | 1,778,502,600 |
| Ebitda | -90,411,000 |
| Ebitda Margins | -0.61897 |
| Enterprise To Ebitda | -4.426 |
| Enterprise To Revenue | 2.739 |
| Enterprise Value | 400,142,560 |
| Eps Current Year | -4.77667 |
| Eps Forward | -4.365 |
| Eps Trailing Twelve Months | -17.93 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.8978 |
| Fifty Day Average Change | 0.7121997 |
| Fifty Day Average Change Percent | 0.09017697 |
| Fifty Two Week Change Percent | 59.44444 |
| Fifty Two Week High | 10.99 |
| Fifty Two Week High Change | -2.38 |
| Fifty Two Week High Change Percent | -0.21656053 |
| Fifty Two Week Low | 3.65 |
| Fifty Two Week Low Change | 4.9599996 |
| Fifty Two Week Low Change Percent | 1.358904 |
| Fifty Two Week Range | 3.65 - 10.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,383,748,200,000 |
| Float Shares | 15,083,511 |
| Forward Eps | -4.365 |
| Forward P E | -1.9725087 |
| Free Cashflow | -49,426,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 228 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.09928001 |
| Gross Profits | 14,501,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04488 |
| Held Percent Institutions | 0.58109003 |
| Implied Shares Outstanding | 22,543,317 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,740,528,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. |
| Long Name | Karyopharm Therapeutics Inc. |
| Market | us_market |
| Market Cap | 194,097,936 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_115373285 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -196,039,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 193,872,517 |
| Number Of Analyst Opinions | 6 |
| Open | 8.89 |
| Operating Cashflow | -75,369,000 |
| Operating Margins | -0.52361 |
| Payout Ratio | 0.0 |
| Phone | 617 658 0600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.61 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 8.66 |
| Price Eps Current Year | -1.8025109 |
| Price Hint | 2 |
| Price To Book | -0.5382259 |
| Price To Sales Trailing12 Months | 1.3288281 |
| Profit Margins | -1.34212 |
| Quick Ratio | 0.977 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -0.577369 |
| Regular Market Day High | 8.89 |
| Regular Market Day Low | 8.465 |
| Regular Market Day Range | 8.465 - 8.89 |
| Regular Market Open | 8.89 |
| Regular Market Previous Close | 8.66 |
| Regular Market Price | 8.61 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 165,095 |
| Return On Assets | -0.41557997 |
| Revenue Growth | 0.116 |
| Revenue Per Share | 13.358 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 22,543,316 |
| Shares Percent Shares Out | 0.24209999 |
| Shares Short | 5,457,102 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,971,195 |
| Short Name | Karyopharm Therapeutics Inc. |
| Short Percent Of Float | 0.2433 |
| Short Ratio | 3.15 |
| Source Interval | 15 |
| State | MA |
| Symbol | KPTI |
| Target High Price | 16.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 63,744,000 |
| Total Cash Per Share | 3.475 |
| Total Debt | 305,944,992 |
| Total Revenue | 146,067,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -17.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.4381 |
| Two Hundred Day Average Change | 2.1718998 |
| Two Hundred Day Average Change Percent | 0.33735105 |
| Type Disp | Equity |
| Volume | 165,095 |
| Website | https://www.karyopharm.com |
| Zip | 02,459-3298 |